Trials / Recruiting
RecruitingNCT06451770
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Verve Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VERVE-201 | Intravenous (IV) infusion |
Timeline
- Start date
- 2024-10-30
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2024-06-11
- Last updated
- 2025-11-28
Locations
10 sites across 4 countries: Australia, Canada, South Africa, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06451770. Inclusion in this directory is not an endorsement.